24 November 18.00-21.00
OUBT is excited to announce that on Wednesday 24th October we will be hosting Jo Brewer, VP Platform Sciences at Adaptimmune.
Adaptimmune specialises in T cell therapy for solid and hematological cancers. They engineer T cell receptors to enhance their affinities for peptide:MHC complexes. They are currently in phase I or II of trials for numerous solid cancers including multiple myeloma, non-small cell lung cancer and head and neck cancer. Having started out as a spin-out from Oxford University, the net proceeds from their completed public offering amounted to over $61 million.
Our speaker, Jo Brewer, will present a talk summarising the scientific approach of Adaptimmune and focussing on the evolution of Adaptimmune from its origins at the Weatherall Institute of Molecular Medicine up to the present day. She will also be sharing her experience of working in Biotech after her DPhil.
The talk will be 30 minutes long and will begin at 6PM in the Biochemistry department seminar room. It will be followed by a short Q&A and a drinks reception, where attendees will have the opportunity to network and meet other biotech enterpreneurs. All welcome, scientists and non-scientists alike!
The seminar room is located on the ground floor and has step-free access. Please let us know in advance if you have any accessibility requirements!